secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
CIK:        0001335105
Form:       8-K
Filed at:   2023-05-10T23:59:59+00:00
Accession:  0001493152-23-016006
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

Lixte terminates unused $10M at-the-market sales agreement with WestPark Capital
--------------------------------------------------------------------------------

- Terminated ATM agreement dated Sept 20, 2021; no sales were ever made under it.
- Agreement allowed sale of up to $10M of common stock through WestPark Capital.
- Termination effective May 9, 2023; no financial impact or penalty noted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1335105/000149315223016006/0001493152-23-016006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1335105/000149315223016006/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-016006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer